Human cathelicidin LL-37 prevents bacterial biofilm formation

被引:5
|
作者
Jacobsen, Andreas S. [1 ]
Jenssen, Havard [1 ]
机构
[1] Roskilde Univ, Dept Sci Syst & Models, Roskilde, Denmark
关键词
ANTIMICROBIAL PEPTIDE LL-37; PSEUDOMONAS-AERUGINOSA BIOFILMS; CYSTIC-FIBROSIS PATIENTS; SEVERE CONGENITAL NEUTROPENIA; HOST-DEFENSE; STAPHYLOCOCCUS-EPIDERMIDIS; EPITHELIAL-CELLS; ANTIBACTERIAL PEPTIDES; ESCHERICHIA-COLI; GENE-EXPRESSION;
D O I
10.4155/FMC.12.97
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Human pathogens often colonize their host by the formation of biofilms. These surface-attached aggregates of bacteria are characterized by a self-produced extracellular matrix, which makes them highly resistant towards antibiotic treatment. Their abilities to adhere to abiotic surfaces (e.g., catheters and other medical devices) also makes bacterial biofilm formation a challenge in modern medicine. Antimicrobial peptides have lately been introduced as a potential class of drug molecules for combating severe hospital-acquired infections. One of these peptides, human cathelicidin LL-37, has recently been demonstrated to bridge innate and adaptive host defence, in addition to facilitating a robust antibiofilm effect at sub-inhibitory concentrations. In this review we will discuss the evidence, potential and challenges for LL-37 as a candidate molecule for therapeutic use.
引用
收藏
页码:1587 / 1599
页数:13
相关论文
共 50 条
  • [21] Human cathelicidin LL-37 rapidly disrupted colonic epithelial integrity
    Kilari, Geeta
    Tran, Jacquelyn
    Blyth, Graham A. D.
    Cobo, Eduardo R.
    BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2025, 1867 (03):
  • [22] Expression of human cathelicidin peptide LL-37 in inflammatory bowel disease
    Kusaka, S.
    Nishida, A.
    Takahashi, K.
    Bamba, S.
    Yasui, H.
    Kawahara, M.
    Inatomi, O.
    Sugimoto, M.
    Andoh, A.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2018, 191 (01): : 96 - 106
  • [23] The Human Cathelicidin LL-37, a Defensive Peptide Against Rotavirus Infection
    Hosseini, Zohreh
    Najafi, Mohammad Bagher Habibi
    Yavarmanesh, Masoud
    Ataei-Pirkooh, Angila
    INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS, 2020, 26 (02) : 911 - 919
  • [24] Design of Antimicrobial Peptides: Progress Made with Human Cathelicidin LL-37
    Wang, Guangshun
    Narayana, Jayaram Lakshmaiah
    Mishra, Biswajit
    Zhang, Yingxia
    Wang, Fangyu
    Wang, Chunfeng
    Zarena, D.
    Lushnikova, Tamara
    Wang, Xiuqing
    ANTIMICROBIAL PEPTIDES: BASICS FOR CLINICAL APPLICATION, 2019, 1117 : 215 - 240
  • [25] Pulmonary defense and the human cathelicidin hCAP-18/LL-37
    R. J. Fahy
    M. D. Wewers
    Immunologic Research, 2005, 31 : 75 - 89
  • [26] Investigation of the interaction between human cathelicidin LL-37 and CpG DNA
    Radford, Michelle
    Avelsgard, Irmamarie
    Craig, Maria
    FASEB JOURNAL, 2014, 28 (01):
  • [27] Low serum levels of cathelicidin LL-37 in leprosy
    Matzner, Michael
    Al Samie, Abdul Rahim
    Winkler, Heide-Maria
    Nemeth, Johannes
    Grasnek, Andreas
    Indra, Alexander
    Bieglmayer, Christian
    Winkler, Stefan
    ACTA TROPICA, 2011, 117 (01) : 56 - 59
  • [28] Cathelicidin LL-37 in Health and Diseases of the Oral Cavity
    Tokajuk, Joanna
    Deptula, Piotr
    Piktel, Ewelina
    Daniluk, Tamara
    Chmielewska, Sylwia
    Wollny, Tomasz
    Wolak, Przemyslaw
    Fiedoruk, Krzysztof
    Bucki, Robert
    BIOMEDICINES, 2022, 10 (05)
  • [29] Serum concentrations of antimicrobial peptide cathelicidin LL-37 in patients with bacterial lung infections
    Majewski, Karol
    Kozlowska, Elzbieta
    Zelechowska, Paulina
    Brzezinska-Blaszczyk, Ewa
    CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY, 2018, 43 (04) : 453 - 457
  • [30] The LL-37 domain: A clue to cathelicidin immunomodulatory response?
    Leite, Michel Lopes
    Duque, Harry Morales
    Rodrigues, Gisele Regina
    da Cunha, Nicolau Brito
    Franco, Octavio Luiz
    PEPTIDES, 2023, 165